| 1110 | Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | abiraterone | oncology | >100k | Not rec. | 20 |
| 1027 | Tebentafusp for treating advanced uveal melanoma | tebentafusp | oncology | >100k | Not rec. | 13 |
| 1018 | Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis [ID1501] | fedratinib | haematology | — | CDF | — |
| 1011 | Cancer Drugs Fund data collection arrangement for the single technology appraisal of belzutifan for treating tumours associated with von Hippel-Lindau disease | belzutifan | oncology | — | CDF | — |
| 975 | Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years | tisagenlecleucel | haematology | — | CDF | — |
| 971 | Therapeutics for people with COVID-19 | dexamethasone,tocilizumab,baricitinib,nirmatrelvir plus ritonavir,sotrovimab,casirivimab plus imdevimab,molnupiravir,remdesivir,tixagevimab plus cilgavimab | respiratory | — | mixed | 44 |
| 962 | olaparib for maintenance treatment of newly diagnosed BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | olaparib | oncology | <20k | CDF | 13 |
| 959 | Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | daratumumab | haematology | >100k | Not rec. | 24 |
| 946 | Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab | bevacizumab,olaparib | oncology | — | CDF | — |
| 943 | MTA Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | — | — | — | — | — |
| 942 | Empagliflozin for treating chronic kidney disease | — | renal | — | — | — |
| 939 | pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | — | — | — | — | — |
| 930 | 177Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies | 177lu vipivotide tetraxetan | oncology | — | — | — |
| 926 | Baricitinib for treating severe alopecia areata | baricitinib | dermatology | 50-100k | Not rec. | 14 |
| 925 | Mirikizumab for treating moderately to severely active ulcerative colitis | mirikizumab | gastroenterology | — | Restricted | 1 |
| 919 | Rimegepant for treating migraine | rimegepant | neurology_psychiatry | — | Restricted | 10 |
| 911 | Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | selpercatinib | oncology | — | — | — |
| 906 | Rimegepant for preventing migraine | rimegepant | neurology_psychiatry | Conf. | Restricted | 8 |
| 905 | Upadacitinib for previously treated moderately to severely active Crohn's disease | — | — | — | Rec. | — |
| 904 | Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | pembrolizumab,lenvatinib,pembrolizumab plus lenvatinib,pembrolizumab with lenvatinib | oncology | 30-50k | Restricted | 10 |
| 903 | Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | darolutamide | oncology | <20k | Rec. | 15 |
| 902 | Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | — | — | — | — | — |
| 900 | Final draft guidance – tixagevimab plus cilgavimab for preventing COVID-19 | tixagevimab plus cilgavimab | infectious_disease | N/E | Not rec. | 20 |
| 898 | Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | dabrafenib plus trametinib | oncology | 20-30k | Restricted | 12 |
| 897 | Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | daratumumab,daratumumab with bortezomib and dexamethasone | haematology | <20k | Restricted | 17 |
| 896 | Bulevirtide for treating chronic hepatitis D | bulevirtide | gastroenterology | 20-30k | Restricted | 19 |
| 895 | Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | axicabtagene ciloleucel | haematology | 50-100k | CDF | 14 |
| 894 | Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | axicabtagene ciloleucel | haematology | >100k | Not rec. | 17 |
| 893 | Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | brexucabtagene autoleucel | haematology | — | CDF | — |
| 892 | Mosunetuzumab for treating relapsed or refractory follicular lymphoma | mosunetuzumab | haematology | N/E | Not rec. | 14 |
| 891 | Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | ibrutinib with venetoclax | haematology | — | Restricted | 9 |
| 890 | Difelikefalin for treating pruritus in people having haemodialysis | difelikefalin | renal | 30-50k | Restricted | 10 |
| 888 | Risankizumab for previously treated moderately to severely active Crohn's disease | risankizumab | gastroenterology | — | Restricted | 9 |
| 887 | Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | olaparib | oncology | N/E | Not rec. | 32 |
| 886 | Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | olaparib | oncology | <20k | Restricted | 10 |
| 883 | Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | tafasitamab with lenalidomide,tafasitamab | haematology | >100k | Not rec. | 9 |
| 882 | Voclosporin with mycophenolate mofetil for treating lupus nephritis | voclosporin | rheumatology | 20-30k | Restricted | 12 |
| 880 | Tezepelumab for treating severe asthma | tezepelumab | respiratory | — | Restricted | 16 |
| 878 | Therapeutics for people with COVID-19 | dexamethasone,tocilizumab,baricitinib,nirmatrelvir plus ritonavir,sotrovimab,casirivimab plus imdevimab,molnupiravir,remdesivir,tixagevimab plus cilgavimab | respiratory | — | Restricted | 34 |
| 877 | Finerenone for treating chronic kidney disease in people with type 2 diabetes | finerenone | metabolic_endocrine | <20k | Restricted | 14 |
| 876 | Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer [ID3757] | nivolumab | oncology | <20k | Restricted | 9 |
| 875 | Semaglutide for managing overweight and obesity | semaglutide | metabolic_endocrine | 20-30k | Restricted | 22 |
| 874 | Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | polatuzumab vedotin | oncology | 20-30k | Restricted | 16 |
| 873 | Cannabidiol for treating seizures caused by tuberous sclerosis complex | cannabidiol | neurology_psychiatry | 20-30k | Restricted | 18 |
| 872 | Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies | axicabtagene ciloleucel | haematology | — | CDF | 3 |
| 871 | Eptinezumab for preventing migraine | eptinezumab | neurology_psychiatry | — | Restricted | 1 |
| 870 | Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | ixazomib with lenalidomide and dexamethasone | haematology | 20-30k | Restricted | 5 |
| 868 | Vutrisiran for treating hereditary transthyretin-related amyloidosis | vutrisiran | metabolic_endocrine | — | Rec. | 2 |
| 866 | Regorafenib for previously treated metastatic colorectal cancer | regorafenib | oncology | <20k | Restricted | 16 |
| 865 | Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | nivolumab | oncology | Conf. | Restricted | 18 |